Deletions and rearrangements involving the long arm of chromosome 11 are not infrequent occurrences in the non-Hodgkin's lymphomas. Recently, a tumor suppressor gene, the multiple endocrine neoplasia type 1 gene (MEN1) was cloned and mapped to chromosome 11q13. To assess the potential involvement of this gene in lymphomagenesis, we examined 94 primary cases of lymphoma and 12 cell lines by a combination of fluorescent in situ hybridization and PCR-SSCP analysis. In our initial analysis of 41 primary B or T lymphomas, MEN1 FISH analysis revealed allelic deletions in 15 cases (three of four B cell chronic lymphocytic leukemias, six of 15 follicular lymphomas, three of nine diffuse large B cell lymphomas, two of five mantle cell lymphomas, one of four Burkitt's lymphoma). To discern whether the MEN1 gene was in fact the target of the deletions, we assessed 20 of these 41 cases and an additional 74 primary lymphomas and 12 cell lines for MEN1 gene mutations using PCR-SSCP analysis. Abnormal SSCP patterns were found in exon 2 in two of the primary lymphoma cases and in one of the cell lines, but not in any of the original cases that showed MEN1 deletions by FISH. Furthermore, sequencing analysis revealed that the abnormal SSCP patterns in exon 2 were the result of a previously described genetic polymorphism (S145S: AGC → ACT), and in one sample, the result of this S145S polymorphism associated with a second nucleotide substitution at position 498 which left the encoded amino acid unchanged. Our study indicates that the 11q13 locus is a frequent target of deletion in lymphoid neoplasms, but that there are no associated mutations of the MEN1 gene. This suggests that the 11q deletions either target another gene in lymphomas, or that the MEN1 gene is inactivated through means other than mutation.
Introduction
Non-random chromosomal translocations are the most characteristic cytogenetic abnormalities occurring in the nonHodgkin's lymphomas (NHL), and have been linked to distinct subtypes of lymphomas. [1] [2] [3] [4] Nonetheless, other types of abnormalities, particularly partial or complete chromosomal deletions, are also frequent. 5 Loss of genetic material from 6q, 9p and 17p are among the most frequent deleted regions reported in lymphomas, [6] [7] [8] [9] [10] but other less well known chromosomal losses have also been reported. Recurring chromosomal deletions, which occur in nearly all types of neoplasia as well as hematologic malignancies, are almost always associated with the loss of a tumor suppressor gene located within the deleted locus. [11] [12] [13] For instance, chromosome 9p deletions are associated with the loss of a cyclindependent kinase inhibitor p16 (CDKN2), 14 while deletions of chromosome 17p are associated with loss of the p53 tumor suppressor gene. 15 Among the lesser known chromosomal deletions in lymphomas are those involving chromosome 11. [16] [17] [18] [19] [20] [21] Deletions of the long arm of chromosome 11 are not uncommon in NHL, and include several reports involving the 11q13 region. [22] [23] [24] [25] [26] [27] [28] This may indicate the presence of a tumor suppressor gene at this locus which may be a target of inactivation during lymphomagenesis.
Over the past decade, the region 11q13 has been the focus of interest of mapping studies and linkage analysis, [29] [30] [31] [32] [33] [34] [35] in the search for the gene responsible for the multiple endocrine neoplasia type 1 (MEN1) syndrome. The MEN1 syndrome is an autosomal, dominantly inherited disorder characterized by the development of multiple endocrine tumors in target organs such as parathyroid, endocrine pancreas and anterior pituitary gland. 36 The gene responsible for the MEN1 syndrome was identified recently by positional cloning 37 and was mapped to chromosome 11q13. Patients with the MEN1 syndrome possess germline mutations in one MEN1 allele. A tumor suppressor function has been proposed based on the observation that loss of the wild-type MEN1 allele occurs in tumors that arise in affected individuals. 38, 39 The function of the protein translated from the MEN1 gene is still unknown.
Allelic (heterozygous) deletions associated with germline mutations of the MEN1 gene have been reported in 63-100% of MEN1-associated tumors. [40] [41] [42] [43] [44] MEN1 gene mutations have also been reported in sporadic non-MEN1-associated tumors such as parathyroid tumors, gastrinomas, pancreatic endocrine tumors and pituitary tumors. [45] [46] [47] [48] Fifteen to 35% of sporadic parathyroid tumors have somatic mutations of MEN1 gene. [45] [46] [47] In sporadic pancreatic tumors and gastrinomas, loss of heterozygosity at 11q13 has been detected in 44 and 19%, respectively, of the 95 tumors analyzed. 40 In sporadic pituitary gland tumors, somatic MEN1 deletions were detected in two of 39 (5%) cases analyzed. 48 Although these tumors are not associated with the MEN1 syndrome, all arise from endocrine tissue.
We undertook this study to determine whether the MEN1 gene could be the target of the 11q deletions found in lymphoid tumors and to establish if this gene could also play a role and contribute to tumor formation in a non-endocrine tissue such as lymphoid tissue. Several tumor suppressor genes such as RB1, p16 or p53 were first described in inherited cancer syndromes (familial retinoblastoma, 49 familial melanoma 50 or Li-Fraumeni syndrome 51 respectively), and have now been shown to be involved in a substantial fraction of many different types of sporadic cancers, including lymphomas. [52] [53] [54] [55] We initially evaluated a subgroup of 41 lymphoid tumors for allelic loss of the MEN1 gene by fluorescent in situ hybridization (FISH) using a cosmid that spans the MEN1 coding region. We followed up this analysis using PCR-SSCP to identify potential mutations in the MEN1 coding sequences in a series of 94 B and T lymphomas and 12 lymphoma/ leukemia cell lines representing a variety of different histologic subtypes.
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Materials and methods
Cases and cell lines studied
One hundred and fifteen patient samples consisting of lymph node, peripheral blood, spleen or other tissue diagnosed histologically as B or T NHL, were selected from case material referred to the Hematopathology Section of the Laboratory of Pathology, National Cancer Institute (National Institutes of Health, Bethesda, MD, USA). All cases were characterized using a panel of antibodies by paraffin section immunohistochemistry. In addition, all samples contained at least 30% tumor cells, well within the sensitivity limits for the FISH and PCR-SSCP analyses described below.
Twelve human B and T hematopoietic cell lines were also studied. These included two EBV-transformed lymphoblastoid cell lines (SB and RPMI-8392), four high-grade lymphoma cell lines (SUDHL6, SUDHL7, SUDHL9 and NUDHL1), one Burkitt's lymphoma cell line (Raji), two T acute leukemia/ lymphoma cell lines (Jurkat, MOLT4), one null-acute leukemia/lymphoma cell line (Nall-1) and two non-lymphoid leukemia cell lines (U937 and K562).
MEN1 allelic deletion analysis
Touch preps were made from frozen tumor specimens. After fixation in methanol-acetic acid (3:1) for 20 min, slides were air-dried, equilibrated in 2 × SSC solution and dehydrated in ethanol series of 70, 80, 90, 100%. In situ hybridization was performed using cosmid clone c10B11 containing the MEN1 gene as a probe. The DNA was labeled with digoxigenin-11-dUTP by nick translation (Boehringer Mannheim, Indianapolis, IN, USA) and ethanol precipitated in the presence of 50× herring sperm DNA and 50× Cot-1 fraction of human DNA. The DNA pellet was resuspended in hybrisol solution (50% deionized formamide/10% dextran sulphate/2 × SSC) with the final concentration of 25 ng/ml. Slides were denatured in 70% formamide/2 × SSC at 72°C for 2 min with the following incubation in cold (−20°C) ethanol series of 70, 80, 90, 100% for 2 min each and air-dried. Probes were denatured at 78°C for 10 min and then incubated for 30 min at 37°C for preannealing. A total amount of 250 g DNA probe was applied on the slide. Overnight hybridization was done in a humidified chamber at 37°C.
Post-hybridization washes were performed at 45°C in 50% formamide/2 × SSC (5 min × 3), 1 × SSC (5 min × 2) and 0.1 × SSC (5 min × 2). Detection was achieved using avidin-FITC and anti-digoxigenin rhodamine (40 min at 37°C) followed by washing in 4 × SSC/0.1% Tween 20 solution at 45°C (2 min × 3 times) and counterstaining with DAPI-antifade (0.25 mg/ml).
Hybridization signals were scored using a Zeiss Axiophot epifluorescence microscope (Thornwood, NY, USA) and twocolor images were captured on a Photometrics CCD camera (Photometrics, Tucson, AZ, USA) using IP Lab image software (Signal Analytics Corporation, Vienna, VA, USA). At least 100 interphases with strong hybridization signals were scored. The presence of more than 15% cells with one MEN1 signal was interpreted as an allelic loss. In previous studies with these probes on normal control tissues, we found a maximum of 5% monoallelic deletions. 48 In the present study, our normal controls consisted of two reactive tonsils, each of which showed 3% of cells with one MEN1 signal. 
PCR-SSCP analysis
Mutation screening was performed by SSCP analysis 56 of the entire MEN1 coding region using PCR primers designed to amplify 13 overlapping products from DNA ( Table 1 ). The primers were all purchased from Biosynthesis (Lewisville, TX, USA). 100 ng of genomic DNA was amplified in a 10 l volume reaction containing 50 pm concentrations of each sense and anti-sense primers, 1 × PCR buffer II (Perkin Elmer, Norwalk, CT, USA), 2.5 MgCl 2 (Perkin-Elmer), 50 m of dATP, dGTP and dTTP each, 2 Ci of ␣-32 P dCTP (specific activity, 6000 Ci/mmol; Dupont NEN, Boston, MA, USA), and 0.5 units of AmpliTaq DNA (Perkin-Elmer). To increase the sensitivity and the specificity of the PCR amplification, 1.4 m of TaqStart Antibody (Clontech Laboratories, Palo Alto, CA, USA) was included in the reaction. The amplification was performed in a Perkin-Elmer DNA 480 Thermal Cycler for 35 cycles consisting of 1 min of denaturation at 94°C, 1 min of annealing at variable temperature depending on the pairs of primers (Table 1) , and 1 min of extension at 72°C, after an initial denaturation at 95°C for 5 min. PCR products were diluted 1:10 in a denaturating loading buffer (95% formamide, 12 mm EDTA, 0.2% bromophenol blue and 0.2% xylene cyanol). The resulting mixture was heated at 94°C for 5 min for denaturation, and chilled in an ice-water bath for 5 min. A 2.5 l sample of the product was immediately loaded onto a SSCP gel ((0.5 × Mutation Detection Enhancement solution (FMC Bioproducts, Rockland, ME, USA)) to be subjected to electrophoresis in 0.5 × TBE buffer at 8 W for 16 h at room temperature. Gels were transferred onto filter paper (3MM Whatman, Maidstone, UK), dried and exposed at −70°C to X-OMAT film (Kodak, Rochester, NY) for 2-8 h.
Subcloning and DNA sequencing strategy
For sequence analysis, variant and wild-type bands were excised from SSCP gels following autoradiography and resuspended in 60 l of water. One l of the eluted DNA sample was used as a template for PCR amplification under conditions similar to those described above for SSCP analysis, except that deoxynucleotide triphosphates were at 200 m and radiolabelled dCTP was omitted. One l of each PCR product was electrophoresed in an agarose gel (SaeKem GTG; FMC Bioproduct, Rockland, ME, USA), and visualized with ethidium bromide. One l of the PCR product was ligated into a pCR2. 1 vector (Original TA Cloning Kit; InVitrogen, San Diego, USA). The ligated product was used to transform competent bacteria (DH5␣; Gibco BRL, Gaithersburg, MD, USA) and the transformants were selected for ampicillin resistance. Recombinant clones were grown up and screened to verify the correct sized insert by agarose gel electrophoresis.
To exclude mutations due to the Taq polymerase, 10 clones containing the correct-sized insert for each variant band were selected, pooled, and automatically sequenced using the M13 forward sequencing primer. The resultant sequences were compared to the genomic DNA MEN1 sequence using MacVector software.
Results
MEN1 allelic deletion analysis
FISH analysis to detect allelic deletions of the MEN1 gene was performed on an initial group of 41 cases including four B cell chronic lymphocytic lymphomas (CLL), 15 follicular lymphomas (FL), five mantle cell lymphomas (MCL), nine diffuse large B cell lymphomas (DLBCL), four Burkitt's lymphoma (BL), two peripheral T cell lymphomas (PTCL) and two lymphoblastic lymphomas of T cell phenotype (T-LBL). As summarized in Table 2 , loss of one allele occurred in 15 of these 41 cases (36.5%). These included three CLL, six FL, three DLBCL, two MCL and one BL cases. Allelic deletions were detected in 30-81% of the interphases examined for each case.
Allelic deletions were not detected in the other lymphoid tumors studied. Three cases (one FL, one MCL and one DLBCL) showed polyploidy with three or four rhodamine MEN1 signals in the majority of the interphases. 
PCR-SSCP and sequence analysis
The above results encouraged us to look further for mutation within the MEN1 gene. A total of 94 cases including 20 of the 41 previous cases that were analyzed by FISH were selected. This included 68 cases of B cell malignancies (10 B-CLL, nine mucosa-associated lymphoid tissue lymphomas (MALT), 10 FL, 10 MCL, 20 DLBCL, nine BL), and 26 cases of T cell malignancies (12 PTCL, 10 T-LBL, and four anaplastic large cell lymphomas (ALCL)). Twelve leukemia/lymphoma cell lines were also screened. Abnormal SSCP conformers were detected in only two cases (one FL and one MCL) (Figure 2) . Neither of these cases showed allelic loss of the MEN1 gene in the FISH analysis. In the interphases examined, the FL case showed a normal pattern with two rhodamine signals per cell, while the MCL case displayed polyploidy with four rhodamine signals in the majority of the interphases. One T-LBL cell line (Jurkat) had an altered SSCP mobility band (Figure 2) . In all three samples, the abnormal conformer was found for the primer set 2c PCR product which spans the 5Ј region of MEN1 exon 2. No alterations in exons 3 to 10 were detected in the 94 cases and the 12 cell lines (data not shown). None of the five cases with mono-allelic MEN1 deletions detected by FISH analysis showed an altered mobility band in the PCR-SSCP gel electrophoresis.
The abnormal conformers identified in the two cases and one cell line were subjected to sequencing analysis. All three tumors showed the same mutation at nucleotide 546 (AGC→ AGT) corresponding to a previously described polymorphism S145S at the codon 145 (Zhuang, personal communication) . In addition, the follicular lymphoma case showed a second mutation at nucleotide 498 (CTC → CTG). This mutation left the encoded amino acid unchanged at codon 129 (leucine → leucine).
Discussion
We analyzed a total of 127 hematologic malignancies including 115 primary NHL cases representing the most common histological subtypes of B and T cell NHL and 12 hematopoietic cell lines, for loss and mutation of a new tumor suppressor gene, the MEN1 gene, located at chromosome 11q13. For this purpose we used a combination of FISH analysis, PCR-SSCP analysis and automated sequencing. Our FISH analysis revealed 15/41 (36.5%) primary cases with monoallelic deletions involving the MEN1 gene locus. However, we failed to identify mutations in any of 127 neoplasms assayed by PCR-SSCP, including five of the 15 cases with mono-allelic MEN1 deletions detected by FISH.
The failure to detect mutations in these cases is unlikely to be due to the inability of our primer sets to identify potential mutations in our cases. The primer sets used in the current study are identical to those published by Zhuang (personal communication) which have been shown to identify the majority (Ͼ85%) of mutations that occur in MEN1 families. Therefore, our failure to identify mutations in the MEN1 gene, despite a relatively high frequency of mono-allelic deletion of the MEN1 locus by FISH analysis, suggests that either the MEN1 gene is not the targeted gene in the deletion, or that the remaining MEN1 allele is inactivated by means other than mutation and deletion.
Although we have not ruled out all possible mechanisms of tumor suppressor gene inactivation, our study has excluded the two most common mechanisms, ie gene inactivation via homozygous deletion, and gene inactivation via hemizygous deletion and mutation of the remaining allele. 55 In MEN1 syndrome families, inactivation of the MEN1 gene occurs through hemizygous deletion and mutation of the alternate allele in 85% or more of the tumors arising in these patients (Zhuang, personal communication and Ref. 58) . Whether promoter methylation or mutation of non-coding regulatory regions plays a role in the minority of cases where mutations or homozygous deletions are not found, is currently not known; however these instances are likely to account for only a small percentage of cases. If the potential abnormalities of MEN1 in lymphomas follow the pattern seen in tumors from MEN1 syndrome patients, our study would suggest that the MEN1 gene is probably not the target of 11q13 deletions detected using the MEN1 FISH probe. Nonetheless, we have not formally ruled out the possibility that the MEN1 gene could have been inactivated through a combination of mono-allelic deletion and promoter methylation, or mutation of noncoding regulatory elements, in the lymphoid neoplasms investigated.
Deletions of the long arm of chromosome 11 have been reported in several cytogenetic studies of NHL. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 59, 60 The most common region of loss is between 11q14 and 11q24, and represents a common aberration detected in chronic lymphocytic leukemia. 16, 59 It has been suggested that this deletion could be an important prognostic factor since patients with CLL and 11q deletion exhibited a more rapid disease progression, a shorter survival time and a shorter treatment-free
Figure 2
Single-stranded conformational polymorphism analysis for exon 2. Aberrant band patterns, distinct from the germ line pattern (GL), are shown in lanes 1 and 3 (FL case and MCL case, respectively). Lanes 2 and 4 are cases with germline pattern. Lane 5 (Jurkat cell line) was run on a separate gel and shows a slightly different migration pattern.
interval than the patients without clonal 11q deletion. 20, 21, 60 A second area of 11q loss is represented by loss of the 11q13 region. Deletions involving 11q13 are reported less frequently than those involving 11q14-11q24, but occur in a variety of lymphoma subtypes. [22] [23] [24] [25] [26] [27] [28] These include small lymphocytic lymphoma, 24, 25 follicular lymphoma 26, 27 and lymphoblastic lymphoma. 28 In the present study we detected allelic loss at 11q13 in 15 of 41 (36.5%) lymphomas, primarily of B cell origin. These included both indolent lymphoid tumors such as chronic lymphocytic leukemia and follicular lymphoma as well as aggressive diffuse large B cell lymphomas. The surprisingly high percentage of cases containing 11q13 deletions in our study indicates that loss of genetic material at 11q13 in lymphoid tumors is more frequent than previously reported, and is consistent with the ability of FISH to detect small interstitial deletions that may not be detectable in classical cytogenetic analysis.
Interestingly, 11q13 deletions occur in a variety of other neoplastic tumors including breast cancer, colon cancer, ovary cancer and melanoma. [61] [62] [63] [64] However, to date, MEN1 gene mutations have not been identified in any of these neoplasms (Zhuang, personal communication and Ref. 65 ) and appear to be confined to neoplasms arising in the MEN1 syndrome setting and to certain types of sporadic endocrine tumors. These studies in solid tumors and ours in lymphomas underscore the possibility that the 11q13 region may contain one or more tumor suppressor genes other than MEN1.
